title: Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells.
abstract: Delayed-type hypersensitivity reactions (DTHR) are mediated by IFN-gamma-producing CD4+ (Th1) or CD8+ T cells (Tc1) and can be prevented by steering T cells toward an IL-4-producing Th2 or Tc2 phenotype. It is currently accepted that T cells can be directed toward a Th2 or Tc2 phenotype only during the initiation of an immune response. Once established, the cytokine pattern of immune reactions is believed to be stable. Therefore, inhibition of DTHR by the induction of Th2/Tc2 responses, termed immune deviation, is considered only as a prevention but not as a therapy of harmful DTHR. Here we demonstrate that therapeutic immune deviation can reverse established contact hypersensitivity (CHS), a Th1/Tc1-mediated DTHR. One or two weeks after induction of CHS, mice received either a single cycle of IL-4 therapy or adoptive transfer of antigen-specific Th2 cells. This treatment generated a novel state of immunity that provided long-lasting protection against tissue destruction and neutrophil recruitment during subsequent antigen exposures. Therapeutic immune deviation of established CHS was dependent on CD4+ T cells and the induction of endogenous IL-4 synthesis. Thus, a population of immunoregulatory Th2 cells persists during advanced inflammatory responses that can be used for therapeutic deviation of established DTHR.
authors.affiliation: Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Biedermann
authors.forename: R
authors.initials: R
authors.lastname: Mailhammer
authors.forename: A
authors.initials: A
authors.lastname: Mai
authors.forename: C
authors.initials: C
authors.lastname: Sander
authors.forename: A
authors.initials: A
authors.lastname: Ogilvie
authors.forename: F
authors.initials: F
authors.lastname: Brombacher
authors.forename: K
authors.initials: K
authors.lastname: Maier
authors.forename: A D
authors.initials: AD
authors.lastname: Levine
authors.forename: M
authors.initials: M
authors.lastname: Röcken
mesh_terms: D019264:Adoptive Transfer; D000485:Allergens / Q000276:immunology*; D000818:Animals; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D004423:Ear; D005260:Female; D006241:Haptens / Q000276:immunology; D007167:Immunotherapy; D015847:Interleukin-4 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D010853:Picryl Chloride / Q000276:immunology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000637:transplantation
chemical_list: D000485:Allergens; D006241:Haptens; D012333:RNA, Messenger; D015847:Interleukin-4; D010853:Picryl Chloride